

PRESS RELEASE
08 April 2024 09:00:00 CEST



Two new studies with ProstaLund's Schelin Catheter® presented at EAU24 in Paris

Two new studies were presented at EAU24, 39th Annual EAU Congress, in Paris – both studies conclude that transurethral intraprostatic injections of anesthetics with Schelin Catheter® enhance the minimally invasiveness of water vapor therapy.

Current analgesic approach for water vapor therapy is transrectal periprostatic block (PNB) or general sedation. PNB is uncomfortable and holds a risk of infection. Sedation poses safety risks and presence of anesthesiology team.

Use of transurethral intraprostatic anesthesia (TUIA) using Schelin Catheter provides a non-invasive, efficient technique for out-patient, office-based procedures.

both studies that were presented; "Multicenter study evaluating the safety and feasibility of Transurethral Intraprostatic Injections of Anesthetics (TUIA) delivered via an innovative catheter to perform minimally invasive surgical techniques for benign prostatic obstructions" by Dr Secco and co-authors and "Transurethral Intraprostatic Injections of Anesthetics (TUIA) and cortisone before rezum treatment shows full pain control and it improves post-operative dysuria" by Dr Siena and co-authors, concludes that TUIA with the Schelin Catheter is a simple technique that shows full pain control before water vapor therapy.

TUIA with Schelin Catheter enhances the treatment and optimizes the need for equipment and set-up. Moreover, adding cortisone to the anesthetics showed a significant reduction of dysuria and catheter discomfort compared to standard general anesthesia and TUIA with only anesthetics.

"We are delighted to see more independent clinical studies on our Schelin Catheter. We are pleased being able offering this unique device for the urological community, enhancing the treatment from different perspectives for both professionals and patients." says Anders Kristensson, CEO of ProstaLund.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com



PRESS RELEASE
08 April 2024 09:00:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Two new studies with ProstaLund's Schelin Catheter® presented at EAU24 in Paris